DBVT DBV Technologies S.A.

NASDAQ
$11.05

DBV Technologies S.A. (DBVT) is expected to report earnings on January 27, 2027, after the market close. The consensus earnings estimate is a loss of $0.75 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.8% since its last earnings release on October 28, 2026.

DBV Technologies S.A. Missed Consensus Estimates
Wednesday, October 28, 2026 · 12:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Jan 27
Wednesday · After Close
Earnings Whisper
-
vs ($0.75)
Rev est $1M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $10.02

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About DBV Technologies S.A.

DBV Technologies SA is an epicutaneous immunotherapy company. The Company is engaged in research and development of patient-friendly therapy for food and pediatric allergy patients.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.